ライフサイエンスコーパス: monthly

1 ctivity were measured in milk obtained twice-monthly.

2 d EO in Scotland over 25 years were collated monthly.

3 VRC01 after birth and then 20 mg/kg/dose SC monthly.

4 ) or placebo daily, and vitamin D or placebo monthly.

5 sychological evaluations of perceived stress monthly.

6 verage lost vision (PRN, -1.6 ETDRS letters; monthly, -1.9 ETDRS letters).

7 mg monthly, 19.1%; 0.5 mg PRN, 16.1%; 2.0 mg monthly, 10.1%; 2.0 mg PRN, 10.5%).

8 from baseline (PRN, 8.5-17.7 ETDRS letters; monthly, 10.1-18.7 ETDRS letters).

9 across ranibizumab arms was evident (0.5 mg monthly, 19.1%; 0.5 mg PRN, 16.1%; 2.0 mg monthly, 10.1%

10 5.9%; 2.0 mg, 25.4%) and treatment regimens (monthly, 26.4%; PRN, 25.0%).

11 ile device location data of over 100 million monthly active samples, we compute origin-destination tr

12 We conducted monthly active surveillance (n = 254; 2624 person-months

13 We modeled monthly activity of sCoVs using site-specific weather da

14 Monthly adjusted rates of antibiotic prescribing were es

15 tad pegol was generally well tolerated after monthly administration over 12 months.

16 ermittent preventive treatment was driven by monthly administration, as compared with single-administ

17 tects from allergen challenge after only 2-4 monthly administrations.

18 Case volume and rates were expressed per 100 monthly admissions, normalizing for seasonal variation.

19 ibercept in a real-world cohort initiated on monthly aflibercept for 3 consecutive injections and obs

20 s performed for all patients at baseline and monthly after injection during the 6-month follow up per

21 s were under artificially lit conditions and monthly ALAN estimates did the best job accounting for s

22 s in Burkina Faso increased participation in monthly AM screening, thus overcoming a major impediment

23 Stool samples were collected monthly and analyzed for HRV, HEV, and HPeV.

24 Monthly and annual occupational doses were described usi

25 s of follow-up, with 120 participants tested monthly and during sick visits.

26 (18/86 eyes [20.9%] and 7/79 eyes [8.9%] in monthly and EOM groups, respectively) than in sham-treat

27 .0004) and 33% (P = 0.009) for pegcetacoplan monthly and EOM, respectively.

28 rs of adult female Ae. aegypti were recorded monthly and grouped by season for three years.

29 5 mg and 2.0 mg ranibizumab) and 2 regimens (monthly and PRN).

30 Patients were randomized into monthly and quarterly 2-mg aflibercept injection cohorts

31 his study of eyes with PDR without DME, both monthly and quarterly aflibercept injection groups showe

32 Q-25 and VFQ-39 composite scores between the monthly and quarterly groups at month 12 (P = 0.947 and

33 Both monthly and quarterly groups demonstrated a statisticall

34 ucted in Tanzania where rodents were trapped monthly and screened for the presence of antibodies agai

35 olled children and collected stool specimens monthly and tested at least 100 specimens annually in th

36 ercept for CMO secondary to CRVO, which used monthly and then as-needed protocols.

37 Memory B cells were counted monthly and when relapse occurred.

38 e examined 3 screening strategies: Yearly, 6-monthly, and 3-monthly, each in addition to the Status q

39 reaction (PCR) -based methods, was performed monthly, and information on IPTp-SP dose was collected.

40 The daily, weekly, monthly, and overall prevalence of GERD symptoms in Iran

41 The daily, weekly, monthly, and overall prevalence of heartburn in Iranian

42 The daily, weekly, monthly, and overall prevalence of regurgitation in Iran

43 rval, 0.0 to 19.9), smaller among those with monthly angina at baseline (2.2 points; 95% credible int

44 iosphere models (TBMs) simulating the daily, monthly, annual and decadal rhythms of carbon assimilati

45 ventions in a hematological malignancy unit: monthly antibiotic cycling for febrile neutropenia that

46 The percent change in average monthly antimicrobial use (all antimicrobial agents, ant

47 ified (i.e., aripiprazole, aripiprazole once monthly, aripiprazole+lamotrigine, aripiprazole+valproat

48 V transmission (0.3-86.1/100PY, by HIV RNA), monthly ART costs ($2,290-$3,780), and HIV per-screen co

49 During days 0-69, mean monthly attack rate was significantly lower with lanadel

50 ian asylum seeker population (representing a monthly average of 28,992 adults) between 1 August 2014

51 increased disability and were monitored on a monthly basis for 6 months.

52 sulotomy rate for each lens was plotted on a monthly basis for the same period, creating a computeriz

53 detect C. limbatus eDNA in the bay on a near monthly basis from spring through mid-fall in 2018 and 2

54 n infections have been detected on an almost monthly basis since 2015, there may be a capacity for H9

55 All patients were evaluated on a monthly basis with fundus photography and fluorescein an

56 stimate under-5 mortality rates (U5MRs) on a monthly basis.

57 ; and aggregated virus results at least on a monthly basis.

58 rvention group also received age-appropriate monthly BCC and SQ-LNS for children >6 months of age.

59 ily in 10 persons with SCI for 4 months with monthly blood testing to quantify the lipoprotein profil

60 her childhood, so she had been submitted to monthly blood transfusions throughout her life, leading

61 idual effect of the insecticide was assessed monthly by exposing susceptible An. gambiae s.s. Kisumu

62 In the time series analysis, monthly cardiac arrest rate in the ICU decreased by 12.4

63 Mean monthly cardiac arrest rate was 17.2 per 1,000 patient d

64 for providers and support staff followed by monthly case conferences.

65 s analyses to measure the effect of PCV10 on monthly case counts by outcome and age group (<1 year, 1

66 Conversely, monthly case data are collected at health facilities but

67 months, and cross-resistance, taxonomy, and monthly changes were characterized under both antimicrob

68 ce-weekly 3,000-IU cholecalciferol, (2) once-monthly cholecalciferol (equivalent to 9,000 IU/week), (

69 ion naltrexone (XR-naltrexone), administered monthly, circumvents the need for daily pill taking, pot

70 ol group) or to receive a cash incentive for monthly clinic attendance in one of two amounts: 10 000

71 ticipants (two males, two females) underwent monthly clinical visits for collection of physiology for

72 9) and GILA (17.5) cohorts compared with the monthly cohort (24.7, P < .001).

73 of nonperfused retina, more commonly in the monthly cohort (n = 8 [44.4%]).

74 (2) at baseline and 1 year (P = 0.70) in the monthly cohort (P = 0.05, monthly vs. quarterly cohorts)

75 Incorporating SQ-LNSs into monthly community-level AM screenings and BCC sessions w

76 or high-risk YMSM in the US, HIV screening 3-monthly compared to less frequent screening will improve

77 ied with a reduction of RNP progression with monthly compared to quarterly dosing.

78 opics and drafted questions to review during monthly conference calls.

79 Life Questionnaire (AE-QoL) was administered monthly, consisting of four domain (functioning, fatigue

80 ies (h(2) = 0.433, c(2) = 0.241) and average monthly cost (h(2) = 0.290, c(2) = 0.302).

81 The monthly cost of ibrutinib would need to be decreased by

82 The monthly cost of the polypill was $26.

83 The monthly CS rate declined across the intervention stages

84 ic and developmental demands with the worm's monthly cycle.

85 .5) concentration by EEMD followed daily and monthly cycles.

86 We use publicly available monthly data from January 2011 through April 2020 on all

87 Patient age, race, cause of ESKD, and mean monthly dialysis duration were most closely associated w

88 erval-censored data, providing adjusted mean monthly differences in age at attaining the pubertal mil

89 f postdischarge malaria chemoprevention with monthly dihydroartemisinin-piperaquine in children who h

90 Further research is needed to evaluate monthly dihydroartemisinin-piperaquine with sulfadoxine-

91 edian cumulative dose of darbepoetin (median monthly dose of 30.9 ug) compared with the titration-dos

92 ith the titration-dose group (53.6 ug median monthly dose).

93 aminophen, naproxen, aspirin) and cumulative monthly dose.

94 weeks (2q4), IAI 2 mg every 8 weeks after 5 monthly doses (2q8), or laser.

95 xposure (week 25 in the groups that received monthly doses and week 27 in the groups that received mo

96 monthly doses of sulfadoxine-pyrimethamine, monthly doses of dihydroartemisinin-piperaquine averted

97 Compared with monthly doses of sulfadoxine-pyrimethamine, monthly dose

98 nts received IAI 2 mg every 8 weeks (after 5 monthly doses).

99 eks, IAIs 2 mg every 8 weeks after 3 initial monthly doses, and ranibizumab every 4 weeks with docume

100 very 4 weeks, IAI 2 mg every 8 weeks after 5 monthly doses, or laser control through week 100.

101 The follow-up was 6 months with a monthly dosing interval.

102 We compared monthly drug treatment costs between benefit levels usin

103 The monthly drug treatment costs in the USA were a median of

104 st once before the expedition (baseline) and monthly during the expedition from February to October.

105 reening strategies: Yearly, 6-monthly, and 3-monthly, each in addition to the Status quo (SQ, 0.7-10.

106 Monthly emission rates differ by >12x, and 3-hourly rate

107 t (PPE) during the COVID-19 pandemic, with a monthly estimated use of 129 billion face masks and 65 b

108 Time to peak BCVA was the monthly evaluation at which the patient's greatest gain

109 standard of care (SOC) or evolocumab 420 mg monthly (evolocumab + SOC) for year 1.

110 he median business with more than $10,000 in monthly expenses had only about 2 wk of cash on hand at

111 Data were synthesized from monthly expert consensus and literature review.

112 ors, equivalent to detecting ODH in 45% of 3 monthly eye examination visits, was associated with sign

113 Median monthly family income fell from US$212 at baseline to $5

114 ome and structural tumour evolution using bi-monthly follow-up scans throughout treatment and disease

115 Samples were analyzed monthly for 1 year for 109 pharmaceuticals/degradates us

116 ing forest proportion (12%-77%) were sampled monthly for 1 year.

117 graphy imaging (Cirrus OCT), at baseline and monthly for 12 months.

118 ted diarrhea in the past two weeks collected monthly for 12 months.

119 Seventeen of them were then followed up monthly for 5 months.

120 inding with sputum smear and culture testing monthly for 6 months and then once every 4 years.

121 econdary-treated sewage, and final effluent) monthly for a 13-month period.

122 IGF levels were assessed in an AAb(+) cohort monthly for a year.

123 The availability of this monthly formulation, delivered by health-care providers,

124 during the year could explain variations in monthly frequency.

125 randomisation), 10 weeks, 14 weeks, and then monthly from 4 to 12 months.

126 Planting was carried out monthly from April to September, and the growth, floweri

127 ned by masked reading center-trained graders monthly from baseline to month 24.

128 Using monthly (from May to October) transcriptomes for three y

129 ed pre- and post-TCZ treatment (8 mg/kg, 6x, monthly) from 12 cAMR patients who failed standard of ca

130 ea with seasonality and drought we conducted monthly ground-based LiDAR surveys over 4 yr at an Amazo

131 The monthly group demonstrated a statistically significant g

132 sons, with the most significant gains in the monthly group.

133 ndophthalmitis occurred in the pegcetacoplan monthly group.

134 4% in the PRN group (301/474) and 70% in the monthly groups (327/469).

135 Symptomatic+asymptomatic-monthly had an ICER <$100,000/QALY only when Re >=1.6; w

136 Least-squares mean monthly HAE attack rate for lanadelumab was compared wit

137 tic events was determined using quarterly (3-monthly) health update questionnaires.

138 The primary outcome was monthly HH adherence (percentage) between baseline and i

139 Monthly HH adherence relative to the intervention increa

140 Monthly high-dose vitamin D supplementation does not pre

141 emissions were modeled and used to calculate monthly high-resolution maps of global characterization

142 All 20 participants could perform monthly home monitoring, though 1 participant stopped af

143 exudative AMD were initially treated with 3 monthly IAI and thereafter as-needed IAI over 12 months.

144 ction, and antibiotic exposure were assessed monthly in a birth cohort of 271 children aged 0-24 mont

145 zation to bovine casein, mice received four, monthly IN immunizations with nanoemulsion formulated wi

146 ime series with comparison group analysis on monthly incidence data collected at the health facility

147 through Blue Cross-Blue Shield [BCBS] Axis); monthly incidence was estimated as the percentage of enr

148 residence [AOR = 2.65;95% CI: 1.16-6.07)]), monthly income of 3501-8000 birr [AOR = 4.54;(1.31-15.7)

149 Low monthly income was associated with lower odds of underta

150 CI 1.29-1.33) after adjusting for age, sex, monthly income, geographic location and residential urba

151 There was a monthly increase in the probability of discharge with ho

152 growth responses of microbial communities in monthly incubations between spring and autumn under diff

153 conditions in a 1:1:1 ratio to receive four monthly infusions of low-dose AK002, high-dose AK002, or

154 weeks (2q4) or every 8 weeks after 5 initial monthly injections (2q8), and eyes imaged with the Cirru

155 ng from RVO of either subtype when receiving monthly injections for a period of 6 months.

156 vision benefit for continuing to treat with monthly injections for persistent HE in the absence of m

157 scans from patients with mCRPC treated with monthly injections of (223)Ra were collected from 7 hosp

158 70 participants were randomized to receive 6 monthly injections of either 1.25 mg bevacizumab (n = 86

159 6 patients who were assigned to receive once-monthly injections of givosiran had sustained reductions

160 vir plus rilpivirine for 1 month followed by monthly injections of long-acting cabotegravir plus rilp

161 layer were obtained at baseline and after 3 monthly injections of ranibizumab in the study group.

162 Monthly injections were more effective than as-needed ap

163 rval cohorts (with and without three initial monthly injections).

164 ng center-guided T&E regimen after 3 initial monthly injections.

165 assigned to aflibercept initially received 4 monthly injections.

166 ye Hospital were reviewed at approximately 3-monthly intervals up to 5 years from the trial randomiza

167 Participants received monthly intravitreal aflibercept or bevacizumab through

168 ere comparable between the PDS 100-mg/ml and monthly intravitreal ranibizumab 0.5-mg arms, with a low

169 /ml, 40-mg/ml, and 100-mg/ml formulations or monthly intravitreal ranibizumab 0.5-mg injections.

170 n the PDS 10-mg/ml, 40-mg/ml, 100-mg/ml, and monthly intravitreal ranibizumab 0.5-mg treatment arms,

171 aseline was similar in the PDS 100-mg/ml and monthly intravitreal ranibizumab 0.5-mg treatment arms.

172 Subjects were randomly assigned to receive monthly intravitreal ranibizumab injections either until

173 In eyes with DME, monthly intravitreal ranibizumab injections resulted in

174 h highly effective drugs, is not superior to monthly IPTp-SP.

175 nts in the high-dose group received a median monthly iron dose of 264 mg (interquartile range [25th t

176 Monthly ISTp with standard RDTs, even with highly effect

177 ected mosquitoes (CVac-chloroquine arm) at 3 monthly iterations, and some received postexposure prima

178 cohort (patients who received three initial monthly IVT-AFL injections followed by regular injection

179 underserved communities, and undergo routine monthly laboratory testing, facilitating a practical, un

180 Stewards participated in monthly learning collaboratives.

181 he HAWK and HARRIER Phase 3 studies, after 3 monthly loading injections, brolucizumab treatment regim

182 In this observational study, monthly longitudinal data on packaged beverage purchases

183 mother-infant pairs and profiled a subset of monthly longitudinal nasal samples from the first year a

184 After reconstructing higher quality MODIS monthly LST data (0.05 degrees * 0.05 degrees ) in 2002-

185 We combined survey and case data to make monthly maps of prevalence between 2013 and 2016.

186 er registrations than in the control period (monthly mean 4386; 32% reduction, absolute difference 4.

187 es by the assimilation of the climatological monthly mean Argo data, the assimilation of glider-obser

188 export of MeHg was evidenced by increases in monthly mean concentrations of unfiltered MeHg (approxim

189 ty at just 1-2 degrees C above their maximum monthly mean temperatures, but some species and genotype

190 primary outcome was change from baseline in monthly migraine days across 12 weeks of treatment using

191 re associated with a significant decrease in monthly migraine days over 12 weeks compared with placeb

192 uares mean (SE) change from baseline in mean monthly migraine days versus placebo: atogepant 10 mg on

193 galcanezumab group had on average 4.1 fewer monthly migraine headache days compared with baseline (1

194 erall mean change from baseline in number of monthly migraine headache days during the 3-month treatm

195 Community-aggregated monthly MiP cases were downloaded from Health Management

196 tters, -1.9 letters, and +0.9 letters in the monthly, monthly plus laser, and PRN plus laser cohorts,

197 her received intravitreal 0.5 mg ranibizumab monthly, monthly ranibizumab with TRP, or 3 monthly rani

198 Florida's postreform monthly mortality rates-for drug-involved deaths, motor

199 200 000 IU vitamin D3 followed by 100 000 IU monthly (n = 2558) or placebo (n = 2552) until late 2013

200 We analysed the monthly number of treatment registrations in April, 2020

201 therapy began subcutaneous evolocumab 420 mg monthly or 420 mg every 2 weeks if on lipoprotein aphere

202 However, there are limited data on monthly or annual doses (or dose trends over time) for t

203 ibizumab or bevacizumab) and dosing regimen (monthly or as needed).

204 onthly treatment were reassigned randomly to monthly or as-needed treatment, without changing the dru

205 month (EOM) or sham intravitreal injections monthly or EOM for 12 months with follow-up at months 15

206 In patients receiving pegcetacoplan monthly or EOM, the GA growth rate was reduced by 29% (9

207 travitreal injections of 15 mg pegcetacoplan monthly or every other month (EOM) or sham intravitreal

208 At monthly or seasonal scales, less common birds experience

209 Pedro Ocean Time-series(3) that were sampled monthly over 5 years.

210 1595% and 197%, respectively, from at least monthly overwash.

211 ve comments was highly correlated with lower monthly percentile ranking (Pearson correlation coeffici

212 We aimed to develop a system to provide monthly personalized feedback and healthier swaps based

213 eek), (3) thrice-weekly placebo, or (4) once-monthly placebo.

214 .9 letters, and +0.9 letters in the monthly, monthly plus laser, and PRN plus laser cohorts, respecti

215 overage (p < 0.001; OR = 1.47), high average monthly precipitation (p < 0.001; OR = 1.14), and high s

216 eas experience relatively evenly distributed monthly precipitation.

217 These trends highlight the utility of monthly prevalence estimates over the four year period.

218 articipants reported upper and lower ARIs on monthly questionnaires.

219 monthly, monthly ranibizumab with TRP, or 3 monthly ranibizumab (loading doses) followed by as-neede

220 re randomized (1:1) to receive three initial monthly ranibizumab 0.5 mg injections, then retreatment

221 After 7 monthly ranibizumab injections, mean BCVA improved by 18

222 ual acuity (BCVA) and change in BCVA after 7 monthly ranibizumab injections.

223 ependently associated with BCVA gain after 7 monthly ranibizumab treatments were younger age (P < 0.0

224 ved intravitreal 0.5 mg ranibizumab monthly, monthly ranibizumab with TRP, or 3 monthly ranibizumab (

225 ance data from Illinois showed that the mean monthly rate of visits related to severe respiratory ill

226 Monthly rates were calculated at the facility unit level

227 matic+asymptomatic-monthly: Symptomatic with monthly re-testing for the entire population.

228 After the intervention, there was a monthly reduction in mortality of 0.0148% (p < 0.01)in t

229 In the intervention, we emailed providers monthly reports of their anticoagulation percentage rela

230 the correlation pattern was opposite at the monthly scale.

231 At both daily and monthly scales, PM(2.5) was positively correlated with C

232 utions more than precipitation at weekly and monthly scales, while precipitation was more important a

233 correlations were examined at the daily and monthly scales.

234 In Burkina Faso, monthly screening for AM of children <2 years of age is

235 ipid-based nutrient supplements (SQ-LNSs) at monthly screenings held by community health volunteers (

236 Ranibizumab retreatment guided by monthly SD-OCT achieved similar vision gains with or wit

237 The highest and lowest monthly self-harm episode rates for the whole asylum see

238 sessions for the first 6 months, followed by monthly sessions for the remaining 18 months.

239 A fifth monthly SMC course is needed to adequately cover the who

240 The parent trial evaluated monthly SMC plus either azithromycin (AZ) or placebo, ad

241 ing from factors related to adherence to the monthly SMC schedule.

242 study performed a longitudinal assessment of monthly spectral-domain (SD) OCT scans to determine MA p

243 , readmission, ambulatory or emergency care; monthly spending 6 months before and following surgery.

244 Monthly sputum cultures, minimal inhibitory concentratio

245 n HZ, children aged 8-13 mo who received >=3 monthly SQ-LNS batch distributions had higher anthropome

246 The mean global correlation between monthly SST anomalies with a three-month time-lag is 0.3

247 combining moisture uptake calculations with monthly stable isotope data observed over five years.

248 strates sex hormone production and undergoes monthly structural changes to release mature oocytes.

249 double-blind, multinational trial comparing monthly subcutaneous evolocumab 420 mg with placebo in P

250 e 2 trial, we administered a series of three monthly subcutaneous injections of either benralizumab (

251 randomly assigned in a 2:1 ratio to receive monthly subcutaneous injections of evolocumab (420 mg) o

252 Both thrice-weekly and once-monthly supplementation effectively increases serum 1,25

253 y adolescent treatment supporter, attended a monthly support group, and received text messages, calls

254 Monthly survival was higher during the breeding period t

255 population; and, 4) Symptomatic+asymptomatic-monthly: Symptomatic with monthly re-testing for the ent

256 eatment group also received 4 biweekly and 3 monthly telephone counseling sessions and choice of Food

257 spatial stream network model to predict mean monthly temperature for 465,775 river km in the western

258 alous temperatures, defined as deviations of monthly temperature from the local average monthly tempe

259 f monthly temperature from the local average monthly temperature over the entire analysis period, aff

260 Mean gain was greater for monthly than for as-needed treatment (difference, -2.4 l

261 e (13) C-discrimination, and delta(13) C(ph) monthly throughout spring, summer, and autumn in Eucalyp

262 without home health care was examined using monthly time intervals, with January 2014 as the interve

263 We analyze monthly time series of 57 US macroeconomic indicators (1

264 e, across one semester (n = 14) at daily and monthly time-scales.

265 ation-Evapotranspiration Index, SPEI), using monthly time-series extracted from 3,100 pixels of fores

266 This indicates two relevant timescales: a monthly timescale with more stability in eating timing t

267 ret temperature fluctuations, over hourly to monthly timescales, to align their growth and developmen

268 on fluxes is typically higher on fine (daily-monthly) timescales and reduces on longer (seasonal-annu

269 ed 2010 annual total and nine of 12 adjusted monthly totals aggregated from the latest version of the

270 ere were no significant associations between monthly treatment costs for solid tumours and clinical b

271 At 1 year, patients initially assigned to monthly treatment were reassigned randomly to monthly or

272 .3 letters for ranibizumab after 6 months of monthly treatment.

273 instituted at enrollment or after 1 year of monthly treatment.

274 112) and sustained reductions in prevalence (monthly trend -0.023 percentage points; -0.044 to -0.003

275 ed from ClinicalTrials.gov on Sept 16, 2019; monthly trends analysis used archived data closest to th

276 When examining monthly trends by processing arrangements, we observed t

277 Adjusted monthly trends for each outcome were examined over the s

278 not used opioids in each month and examined monthly trends in the duration and dose of initial opioi

279 It combined monthly UCTs (approximately US$8.40 /month) with a packa

280 intravenously in a proactive fashion (400 mg monthly, unless the ferritin concentration was >700 mug

281 erapy cycle, then 6-weekly up to 9 months, 3-monthly up to 2 years, and 6-monthly up to 5 years.

282 to 9 months, 3-monthly up to 2 years, and 6-monthly up to 5 years.

283 ited States, and pre-harvest prediction with monthly updates from August.

284 Aggregated monthly use was measured in days of therapy per thousand

285 he models that utilize within-growing season monthly variations performs better compared to the model

286 Monthly versus PRN treatment did not influence MA incide

287 ner-masked SHORE phase 4 study that compared monthly versus pro re nata dosing of ranibizumab in pati

288 C without seizure history were followed with monthly video electroencephalography (EEG), and received

289 OCTA) were performed at baseline and at each monthly visit until 6 months.

290 during which 25%, 50%, and 75% of the normal monthly volumes of symptomatic patients delayed their pr

291 At Re 0.9, Symptomatic+asymptomatic-monthly vs. Hospitalized resulted in a 64% reduction in

292 (P = 0.70) in the monthly cohort (P = 0.05, monthly vs. quarterly cohorts).

293 income, this implies a loss of 4% of average monthly wages for approximately one million Indonesian w

294 totypical influenza season, approximately 7% monthly waning of VE, and that between 0% and 50% of ind

295 Screening 3-monthly was cost-effective (ICER: $4,500/QALY) compared

296 a soft-path irrigation expansion with small monthly water storage and deficit irrigation has the pot

297 ta by dosing schedule (pro re nata [PRN] and monthly) were evaluated separately.

298 Changes in mean monthly wind speed and maximum temperature produce compl

299 Household surveys were collected monthly with approval from Ghana Health Services.

300 avenously in a reactive fashion (0 to 400 mg monthly, with a ferritin concentration of <200 mug per l